Drug intelligence / Profile preview

AMYCOT

Development stage: Unknown
Lead developer: Lacorium Health
Modality: Small Molecules
Administration: Topical

Overview

nailKALM is a topical treatment for fungal nail infections (onychomycosis) developed by Lacorium Health. Its active ingredient is AMYCOT, a proprietary bioactive extract derived from the cyanobacterium Arthrospira maxima (Spirulina). AMYCOT contains high concentrations of proteins, vitamins, and minerals, and is reported to possess antifungal and anti-inflammatory properties. It works by creating an environment hostile to fungal growth and supporting the regeneration of healthy nail tissue. Unlike many synthetic antifungals, it is marketed as a natural, non-toxic alternative and is typically formulated as a topical solution for direct application to the affected nail and surrounding skin.

Brand names: nailKALM
Other names: Arthrospira maximaSpirulina

Targets

Chitin

Beyond the preview

Go deeper on AMYCOT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMYCOT.

Explore the full profile